Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Preferred Stock Liabilities (2023 - 2024)

Beta Bionics' Preferred Stock Liabilities history spans 2 years, with the latest figure at $321.4 million for Q4 2024.

  • On a quarterly basis, Preferred Stock Liabilities rose 22.8% to $321.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $321.4 million, a 22.8% increase, with the full-year FY2024 number at $321.4 million, up 22.8% from a year prior.
  • Preferred Stock Liabilities hit $321.4 million in Q4 2024 for Beta Bionics, up from $261.7 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for BBNX hit a ceiling of $321.4 million in Q4 2024 and a floor of $261.7 million in Q4 2023.